## Innovating, Optimizing, and Advancing Antithrombotic Treatment in Atrial Fibrillation

Monday, October 24 2016 · 12:30 - 2:00 pm · Montreal, QC

## Program Evaluation

On a scale of 1 (poorly) to 5 (greatly) how effectively were each of the learning objectives met?					
After attending this session, you will be able to:					
Integrate recent data from randomized trials and national and international databases and registries					
on the real-world use, effectiveness and safety of oral anticoagulants in patients with AF	1	2	3	4	5
Consider additional treatment scenarios such as AF with concomitant coronary artery disease,					
and recognize the role of various antithrombotic agents for stroke prevention in such settings	1	2	3	4	5
Individualize antithrombotic therapy and practice effective DOAC usage in patients with special					
considerations, whilst balancing risk of bleeding with the benefit of stroke prevention	1	2	3	4	5
On a scale of 1 to 5 (1 = low, $5 = high$ ), please rate this program on the following criteria:					
Originality	1	2	3	4	5
Effectiveness	1	2	3	4	5
Interactivity (25%)	1	2	3	4	5
Please rank the following statements regarding each presentation using a scale from 1 (disagree) to 5 (agree):					
Introduction and Chairing of Symposium — Dr. Laurent Macle					
The chair fulfilled his role	1	2	3	4	5
The topic of the symposium was well introduced	1	2	3	4	5
The chair facilitated the discussion in an interactive manner	1	2	3	4	5
Real-world Evidence for Oral Anticoagulation – Professor Gregory Lip					
The content was well delivered	1	2	3	4	5
The information was relevant to my current practice	1	2	3	4	5
l acquired new knowledge	1	2	3	4	5
Stroke Prevention in Atrial Fibrillation Patients with CAD/ACS/PCI – Dr. L. Brent Mitchell					
The content was well delivered	1	2	3	4	5
The information was relevant to my current practice	1	2	3	4	5
l acquired new knowledge	1	2	3	4	5
Complex Case for Stroke Prevention in AF — Dr. Paul Dorian					
The content was well delivered	1	2	3	4	5
The information was relevant to my current practice	1	2	3	4	5
l acquired new knowledge	1	2	3	4	5

## Program Evaluation (cont'd)

	900 , 0	apply to your practice?	
lease explain:			
/hat future topics would suppo	ort you in your practice?		
lease explain:			
olid you perceive any sources of	commercial hias during the	symnosium? 🗆 Yes 🗀 No	
yes, please explain:	commercial bias during the	symposium: a les a no	
<u> </u>			
Please circle one or two words t	hat hest describe your eyne	rience at this snonsored symnosi	iim•
lease circle one or two words t	hat best describe your expe	rience at this sponsored symposi	um:
	ne old, same old	Interesting	Boring
	ne old, same old	Interesting <b>Impa</b>	Boring <b>Ctful</b>
Wow! Sam	ne old, same old	Interesting <b>Impa</b>	Boring <b>Ctful</b>
	ne old, same old	Interesting <b>Impa</b>	Boring
	ne old, same old	Interesting <b>Impa</b>	Boring <b>Ctful</b>
	ne old, same old	Interesting <b>Impa</b>	Boring <b>Ctful</b>
Wow! Sam	ne old, same old	Interesting <b>Impa</b>	Boring <b>Ctful</b>
Wow! Sam	ne old, same old	Interesting <b>Impa</b>	Boring <b>Ctful</b>
Wow! Sam	ne old, same old	Interesting <b>Impa</b>	Boring <b>Ctful</b>
Wow! Sam	ne old, same old	Interesting <b>Impa</b>	Boring <b>Ctful</b>
	ne old, same old	Interesting <b>Impa</b>	Boring <b>Ctful</b>

Thank You!